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Abstract  4 
Objectives: To determine the association between the α-actinin-3 (ACTN3) R577X polymorphism and 5 
elite team-sport athletic status in three cohorts of European team-sport athletes.  6 
Design: We compared the genotype and allele frequencies of the ACTN3 R577X (rs1815739) 7 
polymorphisms between team-sport athletes (n=205), endurance athletes (n=305), sprint/power athletes 8 
(n=378), and non-athletic controls (n=568) from Poland, Russia and Spain; all participants were 9 
unrelated European men.  10 
Methods: Genomic DNA was extracted from either buccal epithelium or peripheral blood using a 11 
standard protocol. Genotyping was performed using several methods, and the results were replicated 12 
following recent recommendations for genotype-phenotype association studies.  13 
Results: Genotype distributions of all control and athletic groups met Hardy-Weinberg Equilibrium (all 14 
p > 0.05). Team-sport athletes were less likely to have the 577RR genotype compared to the 577XX 15 
genotype than sprint/power athletes [odds ratio (OR): 0.58, 95% confidence interval (CI): 0.34-0.39, p = 16 
0.045]. However, the ACTN3 R577X polymorphism was not associated with team-sports athletic status, 17 
compared to endurance athletes and non-athletic controls. Furthermore, no association was observed for 18 
any of the genotypes with respect to the level of competition (elite vs. national level). 19 
Conclusions: The ACTN3 R577X polymorphism was not associated with team-sport athletic status, 20 
compared to endurance athletes and non-athletic controls, and the observation that the 577RR genotype 21 
is overrepresented in power/sprint athletes compared with team-sport athletes needs to be confirmed in 22 
future studies. 23 
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i. Introduction 29 
The field of genetics and elite athletic performance has made considerable progress in the last 30 
two decades, with various studies suggesting a significant effect of genetics on athletic performance, 31 
even when adjusted for the manifest effect of the environment [1]. The majority of studies, so far, have 32 
focused on genotyping predominantly power or endurance athletes, who represent the physiological 33 
end-points of the sporting continuum. However, the genetic contribution to success in sports that require 34 
a combination of anaerobic and aerobic qualities (e.g., team sports such as soccer and water-polo) has 35 
received limited attention. 36 
Team sports can be considered as mixed-energy system sports. Athletes engaged in these 37 
disciplines are required to repeatedly produce maximal or near maximal efforts (i.e., sprints), 38 
interspersed with brief recovery intervals (consisting of complete rest or low- to moderate-intensity 39 
activity), over an extended period of time. In this situation, both the aerobic and anaerobic energy 40 
systems are important to supply the muscle energy demands during the competition [2]. 41 
The ACTN3 gene, which encodes for the α-actinin-3 protein, is a candidate to influence 42 
individuals’ performance in team-sports. The α-actinin-3 protein is almost exclusively expressed in fast, 43 
glycolytic, type IIX fibres, which are responsible for producing powerful contractions [3]. North et al. 44 
[4] have discovered a common null polymorphism (rs1815739) in the ACTN3 gene, which results in 45 
replacement of an arginine (R) residue with a premature stop codon (X) at amino acid 577. 46 
Approximately 20% of the world population, and 18% of the European population, harbour the ACTN3 47 
577XX genotype and consequently are completely deficient in α-actinin-3 [3]. 48 
The ACTN3 R577X polymorphism has been investigated in the context of human athletic 49 
performance, in both elite endurance and power athletes [5-13], and the general population [14-16], with 50 
the overall conclusion that α-actinin-3 deficiency, as marked by the 577XX genotype, is detrimental to 51 
power performance and possibly beneficial to endurance performance. Recently, we have shown, in a 52 
large group of elite European athletes (n=633), that ‘world-class’ endurance athletes were 3.7 times 53 
more likely to harbour the 577XX genotype than national-level counterparts, and that elite power 54 
athletes were ~50% less likely to harbour the 577XX genotype compared to sedentary controls [17].   55 
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Few attempts have been made to investigate the association between the ACTN3 R577X 56 
polymorphism and team sport athletic status. Santiago et al. [18] showed higher proportions of the 57 
577RR genotype in world-class professional soccer players (n=60) compared with non-athletic controls 58 
and elite endurance athletes. In contrast, no association was found between the ACTN3 R577X 59 
polymorphism and athletic performance in a mixed group of elite Lithuanian athletes [19], in Welsh 60 
rugby union players (n=102)  [20], or in Italian team-sport athletes (i.e., football, basketball, and hockey 61 
players; n=65) [21]. The inconsistent results in the aforementioned studies performed with elite team-62 
sports athletes may be due to an insufficient sample size, associated with the low number of elite 63 
athletes available for analysis.  64 
To overcome the problems of low sample size, we recruited over 200 elite team-sport athletes 65 
from three different European countries (i.e., Spain, Poland and Russia). We then compared the 66 
frequency distribution of the ACTN3 R577X polymorphism between team-sport athletes, elite endurance 67 
athletes, elite power athletes, and ethnically-matched, non-athletic controls, in a large cohort of 68 
European athletes.  Given that team-sport athletes perform multiple sprints and jumps during a match, 69 
and the frequency distribution of the 577RR genotype is consistently higher in power athletes than it is 70 
in controls [5], we hypothesised that the 577RR genotype frequency distribution would be higher in 71 
team-sport athletes compared to the control group. 72 
 73 
ii. Methods 74 
The study was conducted according to the Declaration of Helsinki. Written informed consent was 75 
obtained from all participants, and the study was approved by the ethics committees of Universidad 76 
Europea de Madrid, Spain, the Pomeranian Medical University, Poland, and the Ural State University of 77 
Physical Culture, Russia. 78 
A total of 888 athletes (305 endurance athletes, 378 sprint/power athletes, and 205 team sport athletes) 79 
and 568 controls, from Poland, Russia and Spain, participated in this study. All participants were 80 
unrelated European men and all Caucasians (self-reported) for ≥ 3 generations. According to their 81 
individual best performances, we divided the athletes within each group into two subgroups: ‘elite-level’ 82 
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(competitors in European/World championships or in the Olympic Games) and ‘national-level’, 83 
(competitors in national but not international level events) (Table 1). Of the athletes, 642 (72%) were 84 
classified as elite athletes, and the remaining 246 (28%) athletes were classified as national-level 85 
athletes. Control participants were required to be free of any diagnosed cardio-respiratory disease and 86 
not participating regularly in any competitive or structured sport or physical activity (i.e. performing 87 
less than 3 sessions per week of strenuous exercise such as running, swimming, bicycling or weight 88 
lifting).  89 
Spanish population. The Spanish participants (n=426) included 323 athletes and 103 controls. Of the 90 
athletes 308 were classified as elite and 15 were national level. 91 
(i) 50 elite soccer players (team-sport athletes). Of these athletes, eleven played in teams that had won 92 
the Europe Champions League at least once and two had won the Soccer World Cup. 93 
(ii) 119 elite sprint/power athletes. This group included track and field jumpers (n=13), track and field 94 
sprinters (n=40), and 66 volleyball players. All volleyball players belonged to the Spanish national team 95 
and competed at the international level (including 4 medallists in Olympic Games or World/European 96 
championships).Thirteen track and field sprinters were Olympians during the period 2000-2008. 97 
(iii) 154 endurance athletes aged 20-39 years. This sample included 50 elite endurance runners (the top 98 
Spanish runners during the 1999-2009 period, i.e. mainly 5,000 m to marathon specialists), 50 99 
professional road cyclists who were all Tour de France finishers (including stage winners), and 54 100 
rowers. The rowers included 39 elite athletes who had in the lightweight category in the World 101 
Championships held during 1997-2006.  A total of 139 (90%) of these athletes were elite. 102 
(iii) 103 healthy, non-athletic controls aged 19-32 years. All were undergraduate students from the same 103 
university (Universidad Europea de Madrid, Spain).  104 
Polish population. The Polish participants (n= 695) included 341 athletes and 354 controls. Of the 105 
athletes, 197 were classified as elite and 144 were national-level athletes: 106 
(i) 49 team-sport athletes. This group included ice hockey players (n=25), handball players (n=21), and 107 
soccer players (n=3). Nine (18%) of these athletes were elite. 108 
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(ii) 178 sprint/power athletes. This group included weightlifters (n=43, including 2 Olympic champions, 109 
3 World champions and 10 medalists in World or European championships), sprinters (≤200m, n=48, 110 
including an Olympic champion and 9 medalists in Olympic games or World/European championships), 111 
professional wrestlers (n=72), long jumpers (n=11), and volleyball players (n=4). The group included 112 
118 elite athletes (66%). 113 
(iii) 114 endurance athletes. This group included rowers (n=53, including 14 Olympic/World champions 114 
and 22 medalists in Olympic Games or World/European championships), endurance road cyclists 115 
(n=14, including 7 medalists in Olympic Games or World/European championships), 5,000m runners 116 
(n=12, including 1 Olympic medalist), marathon runners (n=12), 800-1,500m swimmers (n=11, 117 
including 2 medalists in Olympic Games or World/European championships)), 15-50 km cross-country 118 
skiers (n=6, including 2 Olympic champions), and triathletes (n=6, all medalists in the European 119 
championships). The group included 70 (61%) elite athletes. 120 
 (iv) 354 healthy sedentary controls aged 19-32 years (all students of the University of Szczecin).  121 
Russian population. The Russian participants (n=335) included 111 controls and 224 athletes. Of the 122 
athletes 137 were classified as elite and 87 were classified as national-level athletes: 123 
 (i) 106 team-sport athletes. This group included handball players (n=36), field hockey players (n=9), 124 
ice hockey players from the Kontinental Hockey League (KHL), the highest ranked hockey league in 125 
Europe (n=59), and water polo players (n=2). This group included 55 elite athletes (52%). 126 
(ii) 82 sprint/power athletes. This group included skaters competing in events ≤1000m (n=17, including 127 
3 World champions and 3 European champions), boxers (n=34, including 8 World champions and 3 128 
European champions), professional wrestlers (n=10, including 3 European champions), swimmers 129 
competing in events ≤200m (n=8), weightlifters (n=6, including the World Powerlifting Congress man 130 
record holder), figure skaters (n=6), weight lifters (n=6), one strongman (runner up at world 131 
championship and three times Russia’s Strongest Man). This group included 56 (68%) elite athletes. 132 
 (iii) 36 endurance athletes. This group included rowers (n=6), skaters competing in events ≥5000m 133 
(n=22), walkers (n=3, including one winner of the European Cup), mountain skiers (n=2), one swimmer 134 
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competing in events >400m (medalist in European championships, Olympian in 2008), one marathon 135 
runner (European champion), and one duathlete. This group included 26 elite athletes. 136 
(iv) 111 healthy sedentary controls aged 19-32 years. All were students or employees of the Ural State 137 
University of Physical Culture.  138 
We followed recent recommendations for genotype-phenotype association studies provided by Chanock 139 
et al. [22] and Attie et al.[23] . 140 
Genotyping Spanish population. Genomic DNA was isolated from buccal epithelium or peripheral 141 
blood during the years 2004-2008 and genotyping was performed in the Genetics Laboratory of 142 
Universidad Europea de Madrid, Spain. We used the polymerase chain reaction (PCR) method, which 143 
has been applied in previous research [3]. We have replicated the genotype results (in 40% of samples) 144 
in another laboratory (Progenika Biopharma, Parque Tecnológico de Zamudio, Vizcaya, Spain) using a 145 
different method, i.e. a newly developed low-density DNA microarray based on allele-specific probes 146 
[24]. The PCR products were fluorescently labelled and hybridized to the DNA microarray in an 147 
automated platform (Tecan HS4800, Mannedorf, Switzerland), and the microarrays were scanned 148 
(Innopsys S.A., Carbonne, France) using a developed software that converts the intensity of the spots 149 
into the genotype of the polymorphism. For control genotyping, sample analysis was made together with 150 
a DNA control processing with a known genotype of the ACTN3 R577X polymorphism.  151 
Genotyping Polish population. Genomic DNA was isolated from buccal epithelium using GenElute 152 
Mammalian Genomic DNA Miniprep Kit (Sigma, Germany), during the years 2008-2010, according to 153 
the manufacturer’s instructions. We again used the polymerase chain reaction (PCR) method, which has 154 
been applied in previous research [3]. To ensure proper internal control, for each genotype analysis we 155 
used positive and negative controls from different DNA aliquots that were previously genotyped with 156 
the same method.  157 
Genotyping Russian population. Genomic DNA was isolated from buccal epithelium or peripheral 158 
blood, during the years 2009-2011, using the Diatom™ DNA Prep kit (Cat. # D 1025, IsoGene Lab ltd, 159 
Russia). The kit is based on selective DNA on a surface of glass powder in the presence of high 160 
concentration of guanidine isothiocyanate as chaotropic agent. 161 
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Genotyping was performed by using a TaqMan® SNP Genotyping Assays (Applied Biosystems, Foster 162 
city, CA, USA) by use StepOne™ Real-Time PCR System (Applied Biosystems, Foster city, CA, 163 
USA). Assay ID was C____590093_1_. For replication purposes, 75% of the samples were analysed 164 
with a different metod, i.e. PCR-restriction length polymorphism (RFLP), according to a previously 165 
described method [3]. The oligonucleotide primers for this method were synthesized by Evrogen Ru 166 
JSC (Russia). K562 DNA High Molecular Weight from Promega Corp. (Cat # DD2011, Madison, WI, 167 
USA) served as positive control sample at carrying out of both research methods. Genetic profile of 168 
K562 DNA was 577XX in ACTN3 R577X sequence variation.  169 
Chi squared tests were used to test for the presence of Hardy-Weinberg equilibrium (HWE). 170 
Multinomial logistic regression analyses were conducted to assess the association between genotype and 171 
athletic status/competition level. In each case, nationality was controlled for; and analyses were made 172 
comparing 577XX (reference group) vs. 577RX; 577XX vs. 577RR (co-dominant effect); 577XX vs. 173 
577RR and 577RX combined (dominant effect); 577XX and 577RX combined (reference group) vs. 174 
577RR (recessive effect). Significance was accepted when p ≤ 0.05. Statistical analyses were conducted 175 
using SPSS (v. 19). 176 
 177 
iii. Results 178 
Replication of genotyping within Spanish, Polish and Russian cohorts with the abovementioned 179 
methods gave comparable results (data not shown).  180 
Table 1 shows the genotype and allele frequency distributions amongst all participants according 181 
to their nationality. Genotype distributions of all control and athletic groups in each of the three 182 
populations met HWE (all p > 0.05). No significant differences in genotype distribution were observed 183 
across nationalities in control, team sport, power or elite athletes groups respectively. 184 
 Table 2 shows the association between genotype and athletic status for all participants. Team-185 
sport athletes were less likely to have the 577RR genotype compared to the 577XX genotype than 186 
power athletes (p = 0.045), after controlling for the effects of nationality. Power athletes were 187 
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approximately 1.4 times more likely to have the 577RR genotype (as opposed to the 577XX genotype) 188 
than team-sport athletes. 189 
Table 3 shows the association between genotype and competition level (elite vs. national level) 190 
for the team-sport athletes from all countries. No association was observed for any of the genotypes 191 
with respect to the level of competition (elite vs. national level).  As above, nationality was controlled 192 
for in the regression analyses. 193 
 194 
iv. Discussion 195 
We studied the association between the ACTN3 R577X polymorphism and team-sport athletic 196 
status, in a relatively large group of elite and national-level athletes, comprising three cohorts of 197 
European Caucasian athletes. Our main findings were as follows (i) team-sport athletes were less likely 198 
to harbour the 577RR genotype than the 577XX genotype, compared to power athletes (p=0.045), (ii) 199 
the ACTN3 R577X polymorphism genotype distribution was similar in the team-sport athletes, 200 
endurance athletes and the control group, and (iii) the ACTN3 R577X genotype distribution was similar 201 
in the elite-level team-sport athletes and in their national-level counterparts. These findings suggest that 202 
team-sport performance is not significantly influenced by the ACTN3 R577X polymorphism, and that 203 
the 577RR genotype is probably a more important achievement factor for predominantly power 204 
performance events, than it is for team-sport events. 205 
In the present study, the ACTN3 R577X polymorphism was chosen as a candidate to influence 206 
team-sport athletic status as it has provided the most consistent results to date, being the only muscle 207 
gene polymorphism to be associated with performance across multiple athlete cohorts [5]. The 577RR 208 
genotype has been previously associated with elite, power-oriented athletic status (i.e., sprinters, 209 
jumpers and throwers) in several cohorts of Caucasian athletes [7, 10-13, 19, 25], with one exception 210 
[8]. With regards to this, a recent meta-analysis showed a strong association between the 577RR 211 
genotype and power athletic performance especially among Europeans, regardless of the significant 212 
heterogeneity among the groups of athletes [5].  213 
Team sports are intermittent in nature and require the repetition of many powerful movements 214 
such as short-distance sprinting and jumping [26], and these actions require the working muscles to 215 
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produce force at a high velocity [2]. We therefore hypothesis that the 577RR genotype frequency 216 
distribution would be higher in team-sport athletes compared to the control group.  We have shown that 217 
team-sport athletes were less likely to harbour the ACTN3 577RR genotype, compared to the 577XX 218 
genotype, than power athletes. Furthermore, when combining all groups of European athletes, compared 219 
to the team-sport cohort the association between 577RR genotype and power athletic status remained 220 
significant. An explanation for the overall clear association between the 577RR genotype and power 221 
performance, and the unclear association with team-sport performance across multiple independent 222 
cohorts, is that the original association study between the ACTN3 577RR genotype and elite power 223 
performance [12] was performed with Australian (European decent) predominantly elite sprint/power 224 
and endurance athletes. Most of the replication studies were also performed with predominantly 225 
sprint/power athletes. Taken together with current literature, our data collected in the predominantly 226 
power/sprint athletes demonstrate that across different ancestries the ACTN3 577RR polymorphism is 227 
associated with the unique power/sprint muscle phenotype. This is not typical of association studies 228 
involving the ACTN3 R577X polymorphism and team-sport athletes  [19-21] presumably due to the 229 
mixed nature of team-sport events, which rely on both the aerobic and anaerobic energy systems [27]. 230 
Given that team-sport athletes perform multiple sprints and jumps during a match, we 231 
hypothesised that the frequency distribution of the 577RR would be higher in team-sport athletes 232 
compared to controls. However, once we explored this association in a relatively large cohort of team-233 
sport athletes (n=205), all European Caucasians, we found no association between the ACTN3 R577X 234 
polymorphism and team-sport athletic status. We assume that the inconsistent results provided by some 235 
previous reports [19-21] can be attributed to the relatively small sample size of the studied cohorts, and 236 
consequently low statistical power. This supports the need for larger cohorts with clearly-defined 237 
phenotypes to reach more solid conclusion in human association studies. 238 
The ACTN3 R577X polymorphism association with sprint/power performance, in the present 239 
study, is supported by the Actn3 knock-out (KO) mouse model, which was developed to understand the 240 
functional consequence of the ACTN3 R577X polymorphism [28]. The KO mouse-model revealed, 241 
among other findings, that compared with their wild-type (WT) counterparts, Actn3 KO mice (i.e. 242 
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ACTN3 577XX genotype) have (1) lower muscle mass due to lower diameter of the fast twitch muscle 243 
fibres (where α-actinin-3 is primarily expressed); and (2) A significant lower grip strength. Furthermore, 244 
α-actinin-3 deficiency (the 577XX genotype) results in a shift in muscle properties towards those of 245 
slow (type I) muscle fibre. Fast twitch muscles from KO mice have also significantly lower anaerobic 246 
enzyme activity and higher oxidative/mitochondrial enzyme activity, without a shift in fibre-type 247 
distribution [29]. These observations provide plausible explanation for the overall reduced sprint 248 
capacity in humans with the 577XX genotype, and possibly increased in sprint capacity in humans with 249 
the 577RR genotype [1, 30]. 250 
We believe that the results of this carefully controlled study are valid, as we strictly followed the 251 
latest genotype:phenotype study recommendations [22] and all of the following criteria have been met: 252 
all studied participants presented the main study phenotype (i.e., being a professional team sports 253 
athletes). Although we studied three cohorts, participants within and between each cohort were both age 254 
and ethnically-matched (all European Caucasians), genetic assessment was accurate and unbiased, with 255 
genotype distribution being in Hardy-Weinberg equilibrium (HWE) in both cases and controls. 256 
 257 
v. Conclusion 258 
In conclusion, the ACTN3 R577X polymorphism was not significantly associated with team-sport 259 
athletic status, compared to endurance athletes and non-athletic controls. However, the 577RR genotype 260 
was overrepresented in power/sprint athletes compared with team sports athletes.  261 
 262 
vi. Practical implications 263 
 The results of the present study can assist to understand which genetic profiles contribute to team-264 
sport performance. 265 
 Discovering the complex relationship between gene variants and team-sport performance may assist 266 
coaches to optimize training.  267 
 268 
 269 
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ix. Tables 
Table 1. Genotype distribution (Frequency and percentages) of genotypes according to nationality, sport type and level of competition. 
 Spanish (n=426) Polish (n=695) Russian (n=335) 
 Team-
sport 
Power Endurance Control Team-
sport 
Power Endurance Contro
l 
Team-
sport 
Power Endurance Control 
All (n) 50 119 154 103 49 178 114 354 106 82 36 111 
XX 18% 13% 26% 14% 18% 8% 9% 11% 13% 12% 8% 23% 
RX 36% 55% 47% 57% 45% 52% 50% 50% 54% 48% 42% 41% 
RR 46% 31% 27% 29% 37% 40% 41% 39% 33% 40% 50% 35% 
MAF 0.360 0.412 0.497 0.422 0.408 0.339 0.338 0.356 0.401 0.360 0.292 0.441 
HWE-P 
value 
0.302 0.287 0.813 0.210 0.885 0.089 0.454 0.284 0.469 0.958 0.999 0.243 
Elite (n) 50  119  139   9  118  70   55  56  26   
XX 18% 13% 27%  11% 8% 13%  11% 9% 12%  
RX 36% 55% 45%  67% 55% 40%  53% 46% 42%  
RR 46% 31% 27%  22% 36% 47%  36% 45% 46%  
MAF 0.360 0.412 0.500  0.444 0.360 0.328  0.373 0.321 0.327  
National 
Level (n) 
- - 15   40  60  44   51  26  10   
XX  - 13%  20% 7% 2%  16% 19% 0%  
RX  - 67%  40% 47% 66%  55% 50% 40%  
RR  - 20%  40% 47% 32%  29% 31% 60%  
MAF  - 0.467  0.400 0.300 0.352  0.431 0.442 0.200  
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Table 2. Odds ratios of genotypes for athletes and control participants according to sport type. 
 
 
 
Sport Type XX (ref) RX 
 
RR 
 
RX&RR (XX ref) 
 
RR (RX & XX ref) 
 OR OR CI p  OR CI p  OR CI p  OR CI p 
Team-sport 
vs. Power 
1 0.64 0.37-1.12 0.115 
 
0.58 0.34-0.99 0.045 
 
0.60 0.36-1.01 0.053 
 
0.99 0.69-1.42 0.955 
Team-sport 
vs. Endurance 
 
1 0.80 0.46-1.39 0.436 
 
0.85 0.48-1.52 0.589 
 
0.83 0.48-1.39 0.467 
 
1.00 0.67-1.50 0.998 
Team-sport 
vs. Control 1 0.88 0.55-1.43 0.606 
 
0.93 0.56-1.52 0.765 
 
0.90 0.57-1.42 0.652 
 
1.02 0.73-1.43 0.905 
Abbreviations: CI: Confidence intervals; ref, reference; OR, odds ratio. Significant p-value is in bold. 
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Table 3. Odds ratios of genotypes for elite athletes compared to national level athletes in team sports. 
 
 
 
 
 
 
 
Abbreviations: CI: Confidence intervals; ref, reference; OR, odds ratio.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype 
 
Team-sport 
  OR CI p 
XX (ref)  1 - - 
RX  1.64  0.58-4.64 0.355 
RR  1.58  0.53-4.73 0.412 
RX-RR  
(XX ref) 
 1.61  0.59-4.39 0.348 
RR  
(XX-RX ref) 
 1.07  0.53-2.19 0.846 
